As the limitations of conventional viral-vector based gene therapies to deliver optimal patient outcomes become increasingly evident, a fully non-viral approach represents an exciting new therapeutic opportunity.
Joël de Beer - Founder and CSO of Anjarium Biosciences
Anjarium Biosciences AG raised a CHF55.5M ($61M) Series A financing in 2021 led by Gimv and Abingworth, with participation from Omega Funds, Pfizer Ventures and Surveyor (a Citadel company). Funds will be used to creating and delivering a new class of non-viral gene therapies through their unique platform of DNA-based gene vectors and synthetic nanoparticle delivery.
When ambition meets ambition
Anjarium is focused on creating and delivering a new class of non-viral gene therapies to deliver more predictable, enduring, and inclusionary ways to tackle genetic disease throughout a patient’s lifetime. The Company’s versatile platform aims to leverage breakthrough science and expertise at the interface of genetic medicine, synthetic biology and nanoparticle science to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies.
Together, we build a leading company
Anjarium’s innovative approach leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology and nanoparticle engineering to rationally design and produce tissue-targeted gene therapies optimized to improve patient outcomes in a range of serious genetic diseases.
The Company’s unique platform combines proprietary DNA-based gene vectors, natural and synthetic nanoparticle delivery modalities, including its novel Hybridosome™ technology and cost efficient as well as scalable manufacturing solutions.